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Foreword
The analysis in this study focuses on the nature and scope of the expanding role of
information and communication technologies (IT) in the design and development of
healthcare products and services, delivery systems and healthcare administration. The study
traces the potential impact of IT on costs, efficiency and equity as a driver of cross-border
trade and investments and notes that IT can play an important role in enabling the world’s
poor to access essential healthcare products and services in new innovative forms if the
challenges that inhibit its diffusion in developing countries can be addressed through
appropriate policy choices. The study points to the need for further research of how IT
affects costs of diagnosis and treatment with respect to specific disease burdens at
particular locations to resolve tensions between efficiency and equity.
The study highlights policy choices at national and international levels for the
various unresolved challenges associated with distributed enterprising that concern
vulnerabilities for public health because TRIPS, CBD and BWC do not apply in equal
measure in all WTO national jurisdictions. The study is a welcome addition to policy
research on the impact of IT on design and development of trade in healthcare products and
services.
Dr Arvind Virmani




Information Technology (IT) is poised to revolutionise healthcare trade through
new thresholds in human connectivity. This paper focuses on the expanding role of IT in
three distinct but related categories: (a) design and development of healthcare products and
services, (b) delivery systems, and, (c) healthcare administration. Through information
power that IT enables, capacities of decision-makers are continually transformed in how
they link with each other, in the here and now. This not only promotes conventional trade
in services and e-commerce and facilitates worldwide convergence in several aspects of
healthcare management and organisation. However, this process also raises fears and
anxieties because the pervasive nature of IT and its uneven diffusion increase some
vulnerabilities where policy safeguards would be needed. The process of IT diffusion
occurs at many different points of impact in the international economy. Thus, policy
choices have to cater to a wide range of national and regional needs and circumstances
concerning rights to health, rights to trade and rights to development. National policies and
international regimes need to strike a harmonious balance between these sets of rights.
The persistence of unresolved conflicts of rights and conflicts of interests point to
the need for new international arrangements to be  mandated and resourced. The extent to
which this can be achieved is uncertain. This uncertainty is traceable to the ways
responsibility for healthcare, authority to design healthcare products and systems, and the
power to organise healthcare delivery remain separate or come together. The restructuring
of private investments to integrate IT with life sciences in public-private partnerships is a
sign of the growing significance of IT in healthcare. It is also a reminder of how powerfully
IT could be harnessed in  pursuit of millenium development goals.  1
The Role of Information Technology in Designs
of Healthcare Trade 
*
I Nature and Scope of Present Trends in IT and Health
Healthcare needs cannot be met in most countries for the vast majority of the
world’s population from within the prevailing structures of resource allocation. There are
several potential sources of conflict among countries for making and observing rules of
international trade in healthcare goods and services. However,  promoting trade and
protecting health need not be viewed as incompatible goals. Shared commitments on the
use of global healthcare resources can be a powerful uniting force in the world.  Consensus
is constrained by glaring disparities in different regions of the world on quality and
reliability of basic infrastructure, healthcare resources, differences in exposure to disease
and disease burdens, shares of world trade in health services and inadequate awareness,
that adversity anywhere affects prosperity everywhere as amply demonstrated during the
recent SARS epidemic. The enthusiasm for global convergence on healthcare trade is
dampened by differences in national regulations and comes bundled with efficiency, cost
and equity considerations.
Information and communication technologies (IT
1) could revolutionise healthcare.
With the right policy choices, IT is able to promote new thresholds of human connectivity
and is a powerful tool of global convergence through cross-border supply of services.
Firstly, IT enables new opportunities for production of knowledge, the only factor of
production not subject to the economic laws of diminishing returns, and to trade in it for
direct economic benefits. Secondly, international diffusion of new knowledge and best
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1
  The abbreviation ‘IT’ refers to information and communication technologies(ICT) throughout this paper.2
practice opens new ways of improving the performance of health systems. This paper
focuses its inquiry into healthcare problems and solutions impacted by Itwith a view to
help evaluate policy choices. To put this another way: What difference can IT make to
worldwide production and trade in healthcare commodities and  services ? Can IT’s role in
designs of healthcare trade raise revenues and improve healthcare in developing countries ?
Will commercial interests claim priority over  people’s health ?
The most significant feature of IT is its capacity to enable reliable storage, retrieval
and  instantaneous transfer of text, sounds, images and numbers as audio, visual and data
communications. This substitutes and supplements face-to-face contact and transportation.
 Due to this, spatially distant resources and needs connect easily and add new links to 
productive capacity in all aspects of healthcare-development, delivery and administration.
When this productive capacity is recognised as a shareable and exchangeable resource to
be accounted for, IT products and processes acquire a currency akin to money. Producers of
healthcare products and services – regardless of location – can design the outcome of their
efforts to be combinable with each other's efforts and their contributions can also be
electronically traded. In this manner, IT reinforces incentives for trade and investment and
for sharing and distribution of work in ways, for purposes, and with consequences that
cannot fully be envisaged in advance. Thus, IT raises hopes but it also triggers anxieties
over how world health resources and architectural dimensions of cross-border transactions
of the international economy would enmesh with each other.
Cross-border supply is the least developed mode of healthcare services trade
whereas the movement of patients across borders, foreign commercial presence  and the
movement of natural persons have hitherto been, in that order, the three more important
ways of services supply in the sector. IT was first introduced in healthcare at medical
facilities and in medical systems at a time when  efficiency at the delivery-end mattered the
most
2. Trade in IT-assisted healthcare (health resources that use, apply or are facilitated by
IT)  and in healthcare-related IT (IT that arises from, in or for healthcare commodities and
                    
2  World Bank (1993)3
services including powerful diagnostics and investigative tools) expanded rapidly  in the
1990s.  Much of this expansion occurred in healthcare development and healthcare
administration pointing to the need to systematically explore the two-way linkage between
IT and healthcare. However, intangible and invisible services are not easily tracked because
(a) they usually come bundled with products, and, (b) due to differences in national
accounting conventions. The linkages remain under-researched at a time when both IT and
health sectors are in the process of restructuring to converge in important respect. The role
of information technology in healthcare is not well documented and several important
questions arise which are not easily answered.
1. Under what conditions does IT diffusion promote health, trade and development ? 
2. How may policies ensure that higher healthcare costs attributable to IT are
commensurate with benefits ?
3. Would trade based on IT diffusion for healthcare development in business-to-
business mode and for healthcare delivery to patients be efficient and equitable in
developing countries ?
4. Does  IT diffusion in healthcare mitigate disease burdens by reductions in cost per
diagnosis or cost per treated/cured illness ? 
5. What lessons can be learnt from the experience  of uses and abuses of IT in
healthcare in developed and developing countries ?
1. Do new risks and vulnerabilities require new policy safeguards ?
This paper is a modest attempt to fill some of this void with a special emphasis on
research and policy issues of particular relevance to less developed countries.4
IT touches all aspects of healthcare and at many different points of contact.
However, this paper limits its scope to six of the most significant issues arising from IT’s
role in healthcare trade. These  are (1) IT’s role in design of healthcare products and
services (2) IT’s impact on design of healthcare systems (3)  Information power effects (4)
IT’s facilitating role in strengthening public-private partnerships (5) IT-induced
vulnerabilities and IT-aggravated risks, and  (6) Need for global governance.
These issues concerning the impact of IT on healthcare are analysed in the
following sections. Section 2 presents IT’s role in the design of products and services
following the genomic revolution which has completely transformed drug development and
affected many aspects of cross-border supply of healthcare products and services.  Section
3 discusses how and why new ways of organising work locally, nationally and globally
impact healthcare systems when they seek to improve price/quality ratios through cross-
border supply of services. Section 4 sets out some of the important dimensions IT impacts
by bringing the power of information within grasp of individuals, enterprises, and,
governments. Section 5 spells out the rationale for policy options and potential for
partnerships noting some of the conflicts that need to be resolved through new
arrangements. Section 6 presents the evidence on vulnerabilities induced by or enhanced
with the use of IT for which appropriate policy safeguards must be designed. Section 7
spells out the rationale for global governance in several respects due to unsolvability of
certain problems within national policy frames.  The cumulative impact of  IT, relevant to
priorities and perspectives of national and international policy makers, consumers, service
providers, and insurers is evaluated under performance criteria set out in Section 8
emphasising that ITliberates trade in healthcare services from many conventional shackles
but noting that its potential benefits would best be reaped with global solutions and
international safeguards. Section 9 concludes with recommendations emphasising the need
for more research to evaluate policy outcomes and further policy choices.5
II IT’s role in design of  healthcare products and  services
IT has created opportunities for optimising linkages between domestic markets and
exports/imports which is reflected in the design of healthcare products and services.  The
notion of  `TeleMedicine’ thus emerged as the practice of using audio, visual and data
communications for medical consultations, diagnosis, treatment, nursing care, medical
education and transfer of medical data together with a broader concept of `TeleHealth’
which includes TeleMedicine and healthcare management, surveillance, literature and
access to knowledge from a distance, using ICT.  The notion of E-health has gradually
emerged to describe the combined use of electronic communication and information
technology to enable transfers and interactivity.
In the post-genome era, the search for new therapies based on  the study of genes
and proteins linked to diseases has caused an explosion in genetic data. IT-enabled tools
are indispensable for testing large portions of DNA and protein quickly. The new
requirements of speed, economies of scale, standards, simulation and security have rapidly
transformed healthcare into an information-based science driven by IT which is global in
scope
3. New medicines and treatments develop faster and better with cross-border sharing
of work across time-zones and simultaneous clinical testing in trials covering a wider
geographical area-all of which is IT enabled. Trade in  genomic databases involves high
stakes  ever since the human genome was decoded. The correspondence between the
capacity of IT and the economic use of  IT lies at the heart of the matter since information
easily loses meaning, validity, relevance and the taste for it changes rapidly. It is
noteworthy that even at the cutting edge of IT in healthcare development in genomics,
leading firms like Celera could not sustain a business model based on priced information
through online subscriber services for  genome databases and were forced  to diversify into
more value-adding services.
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In 2001, the size of IT-enabled healthcare services is estimated to be about $ 3.1
billion,  of which  about 80 per cent are in developed countries
4.  On-line consultations by
patients and doctors through websites and email, distance referrals, emergency evacuations,
and advance transmission of images and data of patients from ambulances can reduce lead
times of intervention in emergency wards of hospitals. Treatments administered in a shared
mode, distance surveillance of convalescing patients, risk assessments by insurers, distance
consultations on symptoms revealed by patients and observations noted by doctors with the
aid of transferable data from image scanning machines, processing of medico-legal
documents, and cross-border networking for TeleEducation are some of the ways IT’s 
contribution to new products and services is expanding rapidly.
In less developed countries, such innovations are mainly offered at urban locations
in the quality conscious segment of  private healthcare.  Some aspects of TeleHealth such
as TelePathology (requiring special cameras to digitalise specimen slides) and
TelePsychiatry (requiring two-way interactive video conferencing) would remain limited in
the near future, to  developed country locations where sophisticated equipment can be
maintained and its costs afforded. Applications like TeleEducation for medical degrees of
renowned universities in partnership with local institutions and for continuing medical
education of professionals in hospitals, medical colleges and healthcare centres  have great
demand in developing countries.
Healthcare delivery is not the most significant cross-border trade contribution of
IT’s role, constrained as it is by lack of widespread harmonisation of medical curricula and
qualifications, approved drug lists, benchmarked standards, market access barriers such as
economic needs tests (ENTs) and portability of healthcare insurance. Cross-border trade
has been left “unbound” (i.e. countries are free to regulate entry of foreign services)  by
World Trade Organisation (WTO) members in commitments under the General Agreement
on Trade in Services (GATS). Outsourced healthcare administration made up of backroom
operations including medical transcriptions, invoicing, collections, purchases and inventory
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management, accounting, payroll management, continuing education networks linking
hospitals and medical schools, surveys, and research networks presently are a bigger
segment of domestic business and trade where IT’s role is significant and growing.
These opportunities represent potential services exports not only among developed
countries (for example between Norway and Sweden for prenatal chekups and nursing care
in Lapland or between Australia and Canada for TeleConsultations among physicians), but
also from developed to developing countries (for instance, Japan to Thailand, U.S.A to
Mexico, U.K. to Kenya, France to Ivory Coast and Singapore to Indonesia for
TeleDiagnostics and TeleRadiology), from developing countries to developed countries
(for example, Srilanka/India to U.K., U.S.A, Australia and New Zealand for healthcare
administration services which could in future be extended to TeleDiagnostics when
professional qualifications are mutually recognised or harmonised) and among developing
countries (Bhutan, Thailand, Argentina, Nigeria, India, Brazil, China, Nepal, Bangla Desh,
Tanzania for a range of telemedicine applications)
5.  Improved career prospects of doctors
in short supply in developing countries enabled to export their services without movement
as natural persons or foreign commercial presence would reduce the brain drain
IT has enabled doctors and paramedics to use diagnostic packages and decision-
support tools based on the system of international classification of diseases (latest is ICD-
10). Diagnostic measures on ICD-10 were among the first services to be e-commercialised
in Europe. In Japan and Finland, early warning signalling of infectious disease epidemics is
done from patterns of database searches of physicians trying to diagnose from symptoms at
the time of the outbreak of  disease
6 . This kind of IT application could be transported to
any developing country or rendered in a distance mode  enabling quicker intervention when
epidemics  break out although safeguards would be needed  to ensure it does not trigger
panics or false alarms.
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III IT’s impact on design of healthcare systems
IT enables new ways of working and organising work locally, nationally and
globally.
IT is an important consideration in the design of public health systems in less
developed countries where governments need to simultaneously pursue agenda related to
healthcare, development, and trade. Declining budgets and rising costs of healthcare
encourage these innovations also in developed countries. This has significantly enhanced
trade potential. Medical costs in OECD countries have risen to over 10 per cent of GDP
and could reach 15 per cent in the next decade  High cost medical procedures, increased
longevity, ageing populations, and costly medicines are the  main reasons patients, national
public health systems and health maintenance organisations seek cross-border supplies
offering more advantageous price/quality ratios. Within domestic economies of U.S.A.,
Canada and Japan, TeleMedicine services halved traditional costs and increased the
productivity of medical professionals. TeleExpertise has evolved as the basis for branded
healthcare chains with an international scope. Cross-border trade also flourishes within
enterprises following the establishment of foreign affiliates.  Corresponding to innovations
in products and services introduced by IT, designs of healthcare systems could be
simplified to reflect organisational forms based on  syndication  to reduce financial and
administrative burdens. Resource combinations needed for vast undertakings such as
development of new vaccines, testing new procedures for isolating genes and proteins or
proving new specific treatments become organizable, bypassing difficulties associated with
movement of natural persons and foreign commercial presence that restrict inter-firm and
intra-firm service deliveries across national borders. Problems of transferring patient
records, communication of new medical know-how through dissemination of scientific
publications and sharing in peer group fora among medical practitioners are solved. Instant
portability is organised at low cost and electronic storage makes physical acquisition and
storage redundant.
Public healthcare systems can be significantly rationalised with IT. Robotics and
Artificial Intelligence applications enable the positioning of automatic analysers of biotic9
material such as blood, oral fluids and excretions at remote locations. Radiological
scanners in rural areas enable distance consultations with organ specialists. Delivery of
healthcare expertise can be networked through health centres in villages and beyond
extending the reach of healthcare to places where it does not exist. Emergencies can also be
handled more efficiently in countries deficient in transport infrastructure.
Medical professionals such as doctors, nurses, surgeons, anaesthetists, laboratory
pathologists and medical technicians can pool their expertise in new forms and link in ways
that save costs and time. IT enables inexpensive arrangements directly and indirectly
through partnerships, branches, representation offices, subsidiaries, affiliates, franchises,
licences and alliances through on-line tele-services and data transfers and there are
numerous ventures in India, Pakistan, Srilanka, Kenya, and Mexico where transfers of
know-how have been so arranged. The TELEMED project in the European Union has
promoted collaborations in Europe and among African, Carribean and Pacific Basin
countries. New arrangements of profit-sharing are also being structured between medical
practitioners, chemists, pharmaceutical firms, those providing medico-technical services and
medical education institutions. Facilities in developing countries have been quick to seek
affiliation with well known medical schools and hospitals to be able to offer super-
specialisations and also to enhance their image as in the case of Duncan Gleneagles, Apollo
Hospitals and Escorts in India.
The greatest impact is and would remain on the way healthcare development is
organised where the most significant transformative role of IT is observed in how it
induces :
(a) new ways of discovering, synthesising and testing therapeutic products where IT
enables scale, speed, simulation and synergies;
(b) intra-firm cross-border transfers as a source of profitability and growth with 
important implications for how costs are absorbed under differential pricing; and,
(c) through the design of  collaborations that support (a) and  (b).10
Trade in healthcare development is typically characterised by firm to firm
arrangements. Less developed countries are weak in basic telecom and energy
infrastructure and  do not have many scientific laboratories endowed with adequate
financial and human capital. In the past, this made them less likely nodes for linking in
healthcare development networks. Three aspects have changed this now. The drug
discovery process in the new biotechnologies is IT-intensive. It is necessary to process vast
amounts of information at high speeds by distributing the work. Secondly, the drug
development process involves clinical trials in targeted pre-selected populations based on
isolating disease genes among populations with higher than normal susceptibility  to
disease. Thirdly, in trying to exclude those contra-indicated by the composition of  a
therapeutic substance to prove a drug’s safety within limits of notified exclusions calls for
IT-intensity in global trials where IT-assisted screening reduces the scale of clinical trials
as in the case of Genentech’s Herceptin drug for breast cancer treatment
7. Such
developments increase IT intensity in healthcare development and  promote trade across
borders to developed and developing countries. Intra-firm cross-border transfers are the
preferred mode in the design of such healthcare development networks and contribute to
the feasibility of differential pricing when final products are developed and test-marketed
IT enables many different forms of cross-border cooperation that could bring down
the high costs of innovation from about $ 500 million per medicinal drug developed to less
than half of that cost while reducing the lead time of about twelve to fifteen years, on
average, to less than five years in many cases. The logic of profitability in this situation
warrants a calculus that increases consumer spending and margins while costs of
development and delivery are brought down. Firms  syndicate risks in the design,
development, production and distribution of  healthcare products and services where profits
are indicated. This is particularly the case with new drug developments and new treatment
procedures for non-communicable diseases [such as cardio-vascular diseases with
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respiratory complications and malignant neo-plasms], which cause three times more deaths
than communicable diseases
8. In communicable diseases, an important application of IT
has arisen in mapping out characterised vectors using satellite remote sensing data to study
the spread of vector-borne diseases such as  Malaria and Plague.
IT contributes profoundly in expansion of choice for design of research networks in
discovery of new medicines, design of partnerships for testing new therapeutic methods, in
marketing and distribution of prescription drugs, instruments, medical systems as well as
investments by successful health maintenance organisations, managed care systems, and
incorporated forms of general and special healthcare facilities.
Insurers can use IT to pool information and syndicate risk through consolidation if
the insurance sector is open to foreign trade and investment. Cross-border mergers in the
insurance industry for life and non-life businesses are  prompted by new ways to assess
acturial risks based on more reliable data and larger data sets through IT. The price
differences for health insurance reduce.  Insurers have an incentive to encourage "managed
care" facilities to harmonise standards, standardise costs, and reduce the power of other
service providers through consolidated contracts with or as Health Maintenance
Organisations (HMOs). The policy implications of this are discussed in a later part of this
paper (Section 6).
Trade in healthcare administration is, typically, a business to business activity in
which “covered entities” in developed countries (and elite institutions in urban centres of
less developed countries) meet obligations related to record-keeping  and  support services
by farming out work to “business affiliates” at lower wage locations or to the informal
sector in their own countries in a bid to reduce their costs. The role of IT is significant here
because time and cost advantages accrue from distributed enterprising across two or more
time zones. Data processing and transfers can go on 24 hours a day, 7 days a week, 365
days in a year with increased efficiency and reduced cost. Whether this reduction in cost is
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passed on to the consumer or not would depend on policies governing such transactions
and regulations governing prices where applicable. Governments in services exporting
countries also need policies to encourage innovation so that wage cost differentials are not
the only reason for trade and the trade remains sustainable with positive spillover effects.
The dominant mechanism of cooperation in drug discovery is driven by economies
of scale. Consolidation of enterprises of similar business profiles through mergers and
acquisitions is replacing affiliates with more intra-firm transfers among developed
countries. In drug testing, principal firms located mainly in developed countries do most of
the research and development. They are now able to organise division of work
differentiating tasks of different stages and outsource some of the stages to establishments
functioning as affiliates and agents. Human clinical trials are typically first conducted in
developing countries due to fewer restrictions and lower costs. While positive spillover
effects occur in all value chains and consolidations, investments in healthcare development
were unnevenly spread. This is partially offset by research and development capacities
created in developing countries like India aided by technology and scale acquired through
process patent regimes and generic manufacturing for domestic market and exports.
Policies can ensure that developing countries have incentives to undertake IT investments
and participate in international networks of collaborators for drug discovery and 
development
9.    
The demand for increased IT-intensity in healthcare development is stimulated by
service providers who stand to gain from ‘biopower’
10 when databases designed by or on
behalf of pharmaceutical firms, managed care enterprises and insurance agencies become
available to a large transient population of commercial subscribers. New information
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10 ‘Biopower’ refers to bio-information as an alternative  means of domination   to  territories or
commodities.13
increases the number of target molecules at which drugs are aimed
11.  This  reduces the
cost of drug development if the identified target molecules could be proved or disproved
quickly
12. The rate at which candidate molecules are disproved is presently twice the rate at
which new candidate molecules are reported
13
Until recently (1999), pharmaceutical companies typically spent less than 5 per cent
of revenues on IT (compared with 10 percent for other data intensive industries such as
financial services). Since then, they have increased their IT budgets to over 20 per cent of
revenues to compete for in silico research. According to a Frost & Sullivan Study, the
bioinformatics market was estimated to be about $ 3 billion in 2001 (60 per cent of which
is in the U.S) and projected to grow to about $12 billion by 2007
14 Estimates published by
two reputed journals ‘Science’ and ‘Nature’ several months earlier independently confirm
these estimates. International trade in bioinformatics accounts for less than 25 per cent of
this value since most of it is located as domestic business in the U.S. To bioinformatics
must be added other segments to compare the size of the  IT-related healthcare
development industry with IT-related healthcare administration and IT-related healthcare
delivery. Table 1 presents the three segments of the IT-related healthcare markets in U.S.A,
OECD countries (other than U.S.A.) , and the rest of the world.
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Fujitsu and Hitachi.
13 See Neil Holtzman, “Will the Human Genome project revolutionise medicine ?”
http://www.mhsource.com/pt
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Table 1: IT-RELATED HEALTHCARE TRADE YEAR 2001




(excl U.S.A) OTHERS  TOTAL
DEVELOPMENT 7.2 3.8 1.2 12.2
ADMIN 3.1 2.8 0.8 6.7
DELIVERY 1.2 1.3 0.6 3.1
Source: Author
Notes:
(1) These are DELPHI estimates of commercially assessable transactions (including
contracts) on an annualised basis for 2001 based on  five independent surveys (Science,
Nature, Frost and Sullivan, Poste and Financial Times).  
(2)  Reliance has not been placed on values of market capitalisation of biotech firms ($200
billion) or  sales of biotech products ($ 50 billion) for the purpose of estimating IT-
related healthcare.
(3) Trade values are highest in the OECD column at about 50 %. of output.. The
corresponding figure for U.S.A. is about 25 % and for others less than 10 %.
(4)  About $ 82 billion per year worth of patented medicines are to go off patent by 2007. 
Together with the emergence of bioinformatics, pharmacogenomics and proteomics, this
has spurred the healthcare development segment to become the fastest growing segment
of the industry.
(5)  The annual gross value of all electronic transactions was estimated to be $ 95 billion in
Year 2000.
At a global level, the value of IT in healthcare development (and its costs) exceeds
the value of IT in healthcare delivery and healthcare administration put together. There are
significant differences in the composition of IT in healthcare development, delivery and
administration between developed and developing countries. Differences in ways in which
healthcare services trade is accounted and recorded make comparisons difficult.
Decentralised networks  and IT reinforce each other, whereas IT costs and risks require
syndication. These two contrary tendencies pull in different directions.   When higher IT-
intensity affects the creation of value in the industry, it is pertinent to investigate whether
this is associated with concentration of economic power, given the incentives for15
syndication of risk under conditions of higher IT intensity. Healthcare as an industry could
undergo restructuring away from what are termed "cathedral" kind of corporate structures
towards more "bazaar" kind of networks
15.
There are a number of reasons for IT-intensive distributed enterprising to become
the norm.
Firstly, international production and trade in healthcare services is designed around
the concept of sharing in innovation through networks where the registered office is
typically located in a country other than country of origin,  with multiple share listings,
cross-holdings based on alliances, sourcing of inputs from multiple sources and the
extensive use of transfer pricing on intra-firm trade to minimise tax exposure.
Secondly, policies conducive to such arrangements require bargaining power with
host governments, and well established intellectual property rights. Trends towards
increased consolidation through mergers and acquisitions and divestments for arms length
relationships to satisfy competition policies and anti-trust legislation  are part of  acquiring
size and scale to be both cost-efficient and  profitable
16.
Biotech is a high risk-high payoff business where IT intensity can make or break a
company. There are over 150 biotech drugs on the market. Some biopharmaceuticals have
sales of over $ 1 billion. About a third of all new drugs in Year 2001 arose from
biotechnology. However, the number of new medicines approved in the U.S. was down
from 53 in 1996 to 27 in 2000 to just 9 in 2001. In Europe, biotech firms like Cybio,
Genescan, Lion Bioscience and Medigene lost over 90 % of their value in Year 2001
whereas many U.S. biotech firms continued to command higher price-earnings ratios than
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16 Data-based analysis of industrial restructuring trends in healthcare as reflected in asset management
strategies of the biggest 100 firms presented in two tables in an earlier  version of this paper was excised
for the sake of brevity and can be separately made available to interested readers upon request to the
author.16
traditional pharma companies
17. However, the biotech firms havent yet grown to the size of
pharma firms (See Table 2 for a comparison of the top five firms)
Table 2: BIOTECH AND PHARMA FIRMS: A COMPARISON
SALES OF TOP
FIVE BIOTECH






AMGEN              6.3 MERCK         53.0
GENENTECH              2.8 JOHNSON
&JOHNSON
        37.4
SERONO              1.7 PFIZER        33.0
BIOGEN              1.2 NOVARTIS         32.3
CHIRON             1.2 ROCHE        29.7
Source: BusinessWeek, June 2, 2003, p.46
IT has enabled licensing of drug development including the phases of its clinical
trials. When a promising pharmaceutical compound is discovered, it is now the norm to
auction rights to its development. An obesity-related gene discovered by scientists at a
University was auctioned for about $ 20 million
18. In this case, the buying firm then
contracted out its clinical trials and recouped on its investment by value-adding into the
asset with each progressive phase of clinical trials. In another case, Pfizer paid Searle $ 225
million to develop celecoxib, an anti-arthritis compound and farmed out the job. In-
licensing by firms for rights to development is regarded more profitable than outlicensing
of know-how for a fee. The bigger firms usually have large sales and distribution networks
worldwide to exploit their investments on a global scale. Out of  fiftyfive "blockbuster
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drugs" (each contributing to revenues exceeding $ 500 million in a year) marketed in 1998,
fourteen drugs were developed this way
19. Among these fourteen drugs, the cholesterol-
reducing Lipitor tops the list with sales of $2.2 billion. Almost half of the profits of the
world's ten largest pharmaceutical firms arise from such arrangements over externally
sourced products and externally sourced services brokered together to gain time and cost
advantages through substantial cross-border supply of services through IT. In some cases,
as much as 95 % of revenues are derived from such arrangements. It is apparent that this
model is sustainable only if firms quickly spot and capture compounds. If contract R&D
organisations become credible with IT, biotechnology firms would not sell out their
discoveries. IT also enables large firms to target molecules through bigger networks and
laboratories in situations where asset specificities and past human capital investments
matter.
From the published financial statements of pharmaceutical firms, it is noticeable
that the five largest pharma firms significantly increased overseas presence as measured by
foreign assets to total assets ratios, taking advantage of cross-border supply of services.
According to the National Human Genome Resource Institute in U.S.A., genes
contain codes for more than 50,000 proteins in the human body and drugs on the market
presently target only 10 per cent of these. Moreover, the functions of 95 per cent of human
genes are not yet known. This means that firms need to go beyond narrowly researching
one gene at a time and investigate the interplay of genes and proteins along the entire
cellular pathway of a disease. This calls for unprecedented co-operation across a range of
locatiions, and  a range of sciences, using gigantic data-sets at different locations.
Insurers and actuaries are able to use IT to pool records and databases for cost-
effectiveness analysis. Bio-information and medical databases have been commodified and
are tradable. Comparisons of relative efficacy of alternative treatments on a large scale
adds to knowledge that brings down costs of diagnosis and treatment, besides enabling
effective risk syndication by health insurers-domestic and international. This is trade-
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promoting because there is a growing demand for private insurance in all countries where
public healthcare systems are weak or non-existent (including those developing countries
where incomes are rising and there is demand from urban elites). The use of IT in
structuring premia and settling claims encourages firms to set up 24-hour helplines offering
year-round health insurance coverages, which may extend from national to international
through partnerships and direct commercial presence involving foreign direct investments.
 The consolidation of micro-insurance units for healthcare can be enabled the same way as
IT enabled dairy co-operatives in rural areas of less developed countries to achieve
economic scale. Schools that have IT infrastructure readily become nodal points for adult
literacy and adult healthcare too. School-based health insurance schemes with IT systems
have been tested successfully in Egypt in remote locations Field studies from Uganda and
Philippines suggest that reinsurance possibilities can also be introduced in such ventures
although the cost-neutrality in such schemes is not easily achieved 
20. IT has made it
possible for moral hazards and adverse selection to be regulated so that insurance firms can
take into consideration pre-existing disease conditions and public health vulnerabilities to
structure risks properly and yet be supervised for not profiling only those insurance targets
that have low health costs, in the interests of consumer protection.
IV Nature and scope of information power conferred by IT
New networks, contracts and licenses, organisation structures, control systems and
management processes  enabled by IT expand choices and reduce response times for all
concerned. Patients, doctors, hospitals, pharmacies, statutory health authorities and health
insurers can quickly avail, adjust to and offer new responses interactively and rearrange
their responsibilities towards each other. Information power encourages new ways of
exercising power, authority, and responsibility to emerge  around combinations and  trade-
offs involving  choice, costs, efficiency as the criteria by which performance  is judged.
Performance comparisons promoted through openness and accountability raise the
incentives for private and public health systems to compete and perform better.
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Hospitals, medical schools, pharmaceutical companies, related enterprises as well
as local health authorities and health journals and advisory services have all developed and
maintain web pages accessible through internet. About 25 per cent of the content of the
world wide web deals with health and health-related topics covering conventional and
alternate healthcare possibilities which has expanded choice enormously. 
21 Millions of
individuals visit world wide web sites for information which would enable them eat
intelligently, learn to exercise their bodies and to find out other healthcare information
22. IT
enables links to nutrition, diet, exercise, primary healthcare, ante-natal and post-natal care,
hygiene and sanitation  to be located in the proximity of other healthcare and medical
information with obvious synergies. The awareness  of  alternate medicine, and non-
allopathic medical systems is expanding rapidly due to IT. In developing countries, this is
important because the majority of registered medical practitioners (between  56 percent and
80 percent in different developing countries) do not practice allopathy and  three out of
four patients turn to medical systems other than allopathy. Websites enable people to be
more aware of medical systems such as homeopathy, ayurveda, unani, kampo,
acupuncture, herbal medicines and to know where these are available. Alternative medical
systems can be evaluated publicly whereby experiences shared and facts documented
quickly separate biases, conjectures and quackery from what is reliable. Websites get rated
for their quality. Rating agencies like Internetmedicine.com and Healthgrades.com provide
comparative performance data for thousands of hospitals and medical centres. At the
consumer delivery end, e-healthcare players are generally hospitals or medical centres with
solid reputations where the web is used as a supplementary channel rather than a
substitutive one.
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22 Websites like Dynamed  databases offer  links to the International Classification of Diseases (ICD).
Pharmainfonet provides pharmacopia listings. Korean sites like Medmark have links to hospitals, research
centres, patient/consumer information and diseases. Webmedlit, a Canadian supersite links to 23 medical
journals and a Doctor's Guide to the Internet. An Indian site DoctorNDTV.com with more than 150
experts whose credentials are posted on the site with links to drugs, therapies, medical research and
clinical resources was cited in Lancet which has begun to recognise such websites (Lancet, Volume 358,
9281, 18.8.2001). These developments reflect very profound changes in credentialling medical resources
and for price/quality comparisons.20
In enabling doctors, paramedics, patients, insurers and regulators everywhere
(including less developed countries) to become aware of new information quickly,
classification of disease and statistics become more accurate. Timely and precise
information is a pre-requisite of good stewardship and IT provides means to evaluate
responses and establish mechanisms in all areas where logic of decision-making is data-
based. Market failures like non-availability of medicines at health outlets and pharmacies
could also be prevented with better information.  Open information flows on deliveries and
deliverables would set norms, standards and new forms of partnership between private,
voluntary and public sectors. A remarkable feature of IT is its capacity to establish and
disseminate publicly accessible global databases of prices of healthcare commodities and
services.
The risk of erroneous patenting of therapeutic substances in one country of what is
in the public domain in another would  also be reduced. For instance, information about the
patenting of’ haldi’ (turmeric), as "Use of turmeric in Wound Healing" granted by the U.S.
Patent and Trade Mark Office (U.S. Patent 5401504 dated 28.3.1995)  spread quickly
through the world wide web of the internet which spawned campaigns culminating in
successful action by a developing country government (India) to redress the wrong.
V IT’s facilitating role in strengthening public-private partnerships
Private sector participation in financing, production and delivery of healthcare
products and services is a welcome addition to the resource-starved healthcare sector but
also a challenge to the regulation of public health and in ensuring equitable access to the
poor and needy. The sharing of information about facilities, performance, resources, costs
and prices among health authorities, planners, contributors, governments, service providers
and patients is an important aid to promoting better management of healthcare systems
with shared perspectives developed through interactive communications. This reduces the
chance of missing opportunities of trade promotion in healthcare that require businesses
and governments to act in concert.21
The capacity of different people and organisations to work together across complex
networks is an  important element in novel and experimental advances. If communities of
expertise can be connected and resources mobilised together with public interest, political
energies and accountability, IT diffusion could play an important role in public-private
partnerships in managed healthcare
23. Success in any form of accountable and responsible
public-private partnership is based on ongoing reviews, feedbacks and consultations where
informed particpation is the key to success. IT connectivity provides an interactive
platform to exchange ideas and information at low cost which encourages participation and
acts against exclusion. By this process, IT facilitates participation in collaborations by
spawning communications networks with strong incentives to move away from isolated
systems towards risk syndications and risk exchanges, harvesting value through designs of
communications networks.
Aided by IT, the success of Merck's  Ivermectin drug donation for curing river
blindness enabled a hundred million people to be treated in 31 countries with credibility of
the programme  based on  communications networks  which enabled wide  participation
and lots of feedback. This success later spawned one of the biggest public-private
partnerships when Merck joined hands with the Gates Foundation for more such initiatives.
In contrast, Glaxo-Wellcome's anti-Malaria  Malarone drug donation programme in Kenya
suffered from inadequate communication and participation and lack of sufficient
information to conduct a reasoned discourse
24 Failures experienced in drug donation
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programmes due to communication gaps could be easily remedied by IT 
25. IT connectivity
would have enabled facts of the Malarone case to be known at the time it happened with
scope for timely intervention by all concerned instead of the public remaining unaware for
four years until  details were published by scholarly journals like Lancet. Electronic
archiving accessible through internet could simplify dissemination of new knowledge
published by scientific journals.
The core role of IT in healthcare may be understood from the way designs of
healthcare development and delivery enabled and supported by IT include or exclude
people and encourage or discourage their participation in influencing decisions about
allocation of healthcare resources. Participation is a vital aspect of healthcare because
health consumption requires participation in its production at every level starting from 
individual persons (diet, hygiene, lifestyle, belief and trust in one or more medical systems)
to communities (safety, pollution control, sanitation, public hygiene), and nations
(healthcare standards, budgetary allocations, medical education, support to research and
innovation in diagnosis and treatment, and availability of medicines) rendering it uniquely
amenable to communicative technologies, horizontally and vertically in and between these
aggregations.
Public-private partnerships are also required to cope with trading in bioinformatics
and clinical databases. Significant transactions costs arise when contributions are sourced
from a wide range of value creators using different platforms of data transfers and with
multiple claims to proprietary rights over fragments of a whole process before a marketable
product arises. This creates incentives for venture capital, pharmaceutical firms, biotech
                    
25 Malarone had not received regulatory approval as a safe drug in its home country and the need for mass
chemoprophylaxis was not established in Kenya; nor was this drug likely to be an affordable long term
solution in any poor country.  The risk of premature development of drug resistance was exported to Kenya
(after Thailand  turned down a similar offer) for the firm to accumulate experience through clinical data on
this drug being developed mainly for affluent tourists and military overseas missions . The publicity
highlighted that one million doses were offered free but Shretta et. al (2001) have documented that
immediately after 189 courses of treatment in the first six months, Glaxo-Wellcome obtained the
government's permission to sell the drug at its market price, causing a diversion of the medicine from the
welfare sector to the private sector for profit, defeating the stated purpose of the donation..23
start-ups and the State (and its marketised counterparts such as health maintenance
organisations) to make new forms of partnerships in predictive medicine and treatments.
Alliances of universities and research centres with drug developing and clinical trial
enterprises are being established within developed and developing countries and also
between organisations in developed and developing country locations. IT-intensity sustains
such networks contributing to efficiency and equity through rationalisation of financial
constraints as well as non-financial constraints. 
VI IT-induced vulnerabilities and IT-aggravated risks
IT is distinguishable from other technologies because it is process oriented and
transformative in its effects on production, consumption and organisation. Connection
speeds are constrained by availability of bandwidth spectra and the risk of data loss from
contamination  by  viruses and bugs can only be minimised but not altogether eliminated.
While information that IT produces is easily commodified, much of the knowledge that IT-
driven biotechnology incubates is tacit and not eassily reducible as information. This is the
reason that biotech requires science parks and trustful networking anchored in a location.
Placing information on the web poses risks to ownership of intellectual property.
Nor can all information belong to everyone being unsustainable even in its elements,
without being hosted or sponsored. IT products are excludable, divisible and ownable
through introduction of  filters, but cyberspace does not create a domain governed from
within itself insulated from other jurisdictions
26.  The reliance on IT obliges adaptation to
ever-changing new technical norms and to new rules introduced by regulators or censors.
Policies and safeguards need to be envisaged to harmonise private and public interest so
that IT is not used as a tool to propagate harmful substances and drugs. There could be four
different ways in which IT as  a media channel could be protected from undesirable  traffic:
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flawed because IT flows depend on what regulators would allow and the conditions they impose.24
1. International legal agreements on e-commerce prohibiting certain products
and services as “global public bads” from the purview of e-commerce.
2. Introduction of rules by regulators with enforceable penalties.
3. The use of IT itself to neutralise the canvassing of “sins and bads” with
counter-campaigns disclosing more information on health hazards.
4. Censorship of cyberspace through filters
IT has enabled screening of people for susceptibility to diseases and also the
targeting of new drugs to pre-defined genetic profiles. Policies must ensure  that genetic
stratification does not create new social class structures with genetic upper classes and
genetic lower classes. Priorities of healthcare developers and deliverers would need to be
harmonised within the budgetary constraints of healthcare contributors and recipients in
different countries with different quanta of healthcare resource availability.
Healthcare needs, resources and IT capacities  in less developed countries differ
from developed countries although IT-enabled resource linkages and exchanges could
impact quality, efficiency and equity dimensions of healthcare everywhere. The globalised
healthcare industry is growing faster than any other industry and offers incentives to
participate in its designs. Imminent restructuring of authority and responsibility in national
spaces forces all concerned to respond in self-interest.  Resource constraints in less
developed countries pull investments into IT to the extent allocation of scarce resources
can be improved on efficiency and quality considerations in private healthcare and on
grounds of efficiency and equity in public healthcare. Safeguards are needed to ensure that
global solutions for market standardisation and control  (of health norms or  IT standards and
specifications) are not limited to a few players with greater access to healthcare or IT
resources.
Since IT-intensity  is one of the causes of rising healthcare expenditures, policies
would need to ensure, through appropriate cost-benefit analysis, justifications and25
affordability of such increases on grounds of efficiency or postive externalities, particularly in
the case of less developed countries
27. If IT attracts resources away from actions which have
large positive externalities (or the benefits to those who derive livelihoods from IT’s role in
healthcare are less than  the increased costs of healthcare commodities and services), 
Specific regional studies at the level of local communities would be useful to understand  and
evaluate these processes because the available data is meagre.
IT has enabled certain kinds of abuses that would have previously not been possible
to execute on a large scale. Pharmaceutical firms provide incentives to pharmacies to sell
prescription drugs over the counter without prescriptions in less developed countries. IT has
made it possible for chemists, pharmacies, and extension counters of clinics and hospitals to
build databases and push products using retail store models of incentives -something that
would be impossible in  developed countries where firms target doctors, not individual
chemists or pharmacies. This is also a source of concern to health insurers organising the
contribution side of such a market through health insurance schemes.
Overconsumption of medical products and services is one of the leading causes of
rising healthcare costs. Health insurance schemes get dragged into bearing the burden due to
improvements in medical procedures to prolong life, ageing populations and the tendency of
buying insurance according to needs without necessarily contributing to it on the basis of
means. There is also the danger of supply-induced demand.  For instance, schools that
introduce school-wide healthcare insurance schemes are pressurised in direct marketing
campaigns to dispense medicines and treatments with little regard to needs. The marketing of
Ritalin, Metadate and Adderall (through commission agents armed with IT-databases) to
school authorities for "attention deficit hyperactivity disorders" in school children to make
children more docile for teachers has already occurred without parents' knowledge in some
instances. Such malpractices would be difficult to control in societies where establishments
like schools have  power over parents as in cities of developing countries where demand for
places in private schools exceeds supply.  IT-enabled databases have also been used to target
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school children covered by health insurance through commission agents acting together with
school systems to push children into medical treatments they do not need by inducing them
through small treats as incentives. Similarly, "managed care" alternatives could take perverse
forms for adults too when IT promotes disease management models bypassing medical
expertise by conducting what is termed in medical parlance as "wallet biopsy" (scrutiny of the
means to pay). 
The recording of health data does not merely concern medical histories, medicine
inventories and doctors´ addresses maintained for the benefit of patients. Clinical and
personal data of patients and doctors routinely stored in medical facilities could be traded
without informed consent for market research, insurance and other commercial purposes to
target profiles. IT has enabled this to be done in centralised databases on a large scale for
whole communities, regions and countries. Some governments already directly trade in their
monopoly of control over such information as in UK and China. Other governments as in 
Estonia, Kenya, Nigeria, Tonga and Iceland license this trade through firms registered in off-
shore or other grey and distant jurisdictions
28. The licensing of healthcare databases for
commercial profit with or without the prior consent of individuals whose data is so traded
enables collecting or trading DNA information on specific groups and communities without
their knowledge or consent.
New vulnerabilities point to the need for policy safeguards to deal with the following
problems:
(a) Rights to privacy and personal data protection are easily breached  because healthcare
databases have to be kept open for updating old records and for initiating new records and
entries. So confidentiality cannot be secured by coding the data or disconnecting the data
from personally identifiable features. Patients could lose trust in the confidentiality of
their conversations with their doctors unless this problem is solved. Demands of payment
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firm with a ‘Delaware registration’ to link with subsidiary affiliates for healthcare database trading
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for parting with bio-information could arise.
(b) Medical databases are easily linkable to databases of genealogy, castes, tribes, clans,
ethnicity, and genetics. The principle that such data be stored only at its place of origin
and used only for the original purpose for which it is collected is difficult to enforce.
Personal data on whole nations and ethnic groups could  be exploited in ways that
endanger public health (Mathur, 2002). Without enforceable international agreements,
no individual or social institution is in any position to supervise the use of healthcare
databases. In the hands of mercenaries and rogue states, healthcare databases could be
misused to trigger complex humanitarian emergencies or for fostering permanent
dependencies using biopower as a means of disruption.
(c) The scientific and commercial value of health databases is limited to those who have the
means to maintain and update these databases and link them to other databases in their
possession. This could accentuate the information and technology gaps between
developed and less developed countries
29.
(d) IT enables decoding of personal data using genotypes and phenotypes as personal
identifiers and the design of novel organisms against which vaccines or antibiotics
would be useless. When private information held in public databases is commercially
traded by privatising public domains, rights of natural persons get transposed with
rights of artificial juridical entities. Since intellectual property rights are private rights,
international regimes for e-commerce in healthcare and consumer protection are needed
for what remains outside the public domain.
(e) The risk is greatest  when exclusive ownership or control of healthcare databases is
lawful. The entirety of medical records of a community are a non-renewable single good.
Yet, the incentive for governments in less developed countries to sell or license such
information to raise resources from the private sector is considerable. This is particularly
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the case when therapies are developed on the basis of databases of communities offered
free drugs in exchange. There is growing awareness that firms need to repay communities
for vital bio-information. DNA information of an individual is worth about $100,000 in
commercial value which could be greater than the cumulative income receipts of
individuals in poor countries over a lifetime
30. This clearly points to the need for
biobanks which could profitably and securely be designed and constituted under
international control as independent global healthbanks or by extending WHO’s
mandate to accommodate them within its umbrella. 
(f) Unrestrained IT in healthcare implies the end of privacy.  If the restraining instrument is
government executive control as in Malaysia and the U.K, the danger is arbitrariness. In
contrast, IT restrained by parliamentary laws could lead to wasteful litigation. If restrained
only by market incentives it would make it too easy and too profitable for businesses to
act contrary to the interests of other constituents. This situation urgently requires new
forms of public-private partnership.
(g) If it is known that normal data protection controls can be easily bypassed by   
powerful interests in a vital area like health in any particular country, it would also have
consequences for trade and development in other sectors due to loss of confidence in
that country’s capacity to provide adequate data protection for business secrets and
intellectual property rights.
(h) With IT, the inventory of possible symptoms, physiological and mental, is quickly
recognised also in patients who suffer from minor ailments and who could recover
anyhow, with or without treatment. When treated, such patients recover rapidly. This sort
of change in diagnosis rather than in treatment may re-allocate healthcare resources and
increase costs. IT could also increase the cost of healthcare in other ways when “internet-
positive patients” confront doctors with medical information obtained from the web
which doctors themselves may not have found time to evaluate.
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(i) With reference to insurance consolidation in Section 2, trading in clinical and genetic
databases enables insurers to acquire information to exclude beneficiaries of specific
profiles who pose higher risks to predictable disease susceptibilities. Secondly,
centralised healthcare databases of more than one million records cannot be securely
designed and administered
31. Due to these hazards, the role of IT in organising the
contribution side of healthcare remains undeveloped for the present.
(j) The promotion of IT as a means to stimulate cross-border connectivity for  growth and
employment through trade and foreign investment cannot be easily accomplished when
international networks bypass locations where doctors, IT specialists and other scientists
and technologists do not already relate to each other. According to the reports of the
European Union’s TELMED project, there is little evidence even in developed couintries
of any strategic development of telematic healthcare outside pilot programmes, except in
medical imaging, community health applications, and health care administration systems
involving smart cards and electronic patient record transfers.
VII Need for global governance
The responsibilities for healthcare and IT are naturally global in certain respects
although not well reflected in the organisation of either of them. Healthcare policy is
conventionally the responsibility of local and national governments whereas IT is mainly
innovated through  private initiatives. Research and Development costs have risen and
risks are greater because much of the work is on diseases which are not well understood
and a large number of patents are due to expire by 2005, forcing the pace.
Cross-border data transfers in healthcare development, delivery and administration
and have increased manifold and continue to grow. The normative aspects of these data
transfers (and authority to exercise control over them) are designed to technical standards
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but are not determined by technology alone
32. These flows are governed  through
conceptions of what transactions are regarded  fair on the basis of negotiated
international regimes such as the General Agreement on Trade in services (GATS)
and Trade Related Intellectual Property Rights (TRIPS). Such arrangements at the national
and international level need to cater to concurrent pursuit of rights to health, rights to trade
and rights to development while striving for a dynamic balance between these sets of
rights. There is acute concern for what the TRIPS regime would do to availability of
affordable essential drugs for the poor and whether it would adversely impact health or
trade or development.
Historically, healthcare was descriptive with a legacy of disarray in data management
including storage and annotation with no agreement on standards for shared databases and
software designs.  Several standards persist for transmitting images, data and for making
electronic medical records. Comparability of care is not assured. The present approaches of
Bio-ontology consortium, Bio-pathways Consortium, Life Sciences Domain Task Force and
the Object Management Group differ very much from each other and consensus is not
imminent
33. An indirect recognition of this IT problem in healthcare comes from the plan
made at the BIO 2001 San Diego Conference by over fifty pharmaceutical, biotech and IT
firms to work together to develop bioinformatics standardisation to end the chaos, confusion
and avoidable high costs presently caused by use of dozens of incompatible data platforms.
GATS commitments on telecom access could facilitate or preclude cross-border
trade in health services and are also a cost factor. The protection for IT itself was legislated
in TRIPS and computer programmes brought under Article 2 of the Berne Convention,
1971 as literary works by the 1996 Geneva Amendment with separate further protection for
databases (but not for data)  under  Article 5 of the Geneva Amendment. Programme
carrying signals transmitted by satellite were already covered under the Brussels
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Convention of 1974 (Brussels Convention Relating to the Distribution of Programme-
Carrying Signals, May 21, 1974) to prevent distribution of signals except to intended
recipients. The implementation of the Ministerial Declaration on Trade in IT products
(known as ITA-I) concluded in Singapore in December 1996 among 29 countries
(including all 15 EU countries and U.S.A and Canada, among others) was delayed because
signatories did not have the threshold proportion of world trade in information
technologies required for the agreement to take effect which had to wait for an adequate
number of countries representing IT trade (China, India, Thailand) to join the agreement.
The ITA-II round for zero tariff on an expanded product coverage could not be concluded
and the non-tariff measures work programme adopted on 13.11.2000 remains a modest
step. The Washington Treaty on Intellectual Property in Respect of Integrated Circuits,
1989 (under WIPO) protecting topographical designs of integrated circuits has not entered
into force, to date. The Rome II recommendations on enforceability of consumer rights for
cross-border supply in national jurisdictions are contrary to the EU Directive on Electronic
Commerce which recognises enforceability only in jurisdictions where the service provider
is located. Thus, there are several unresolved IT problems awaiting global solutions.
The authority for one’s own well-being is partly delegated by individuals as
“consumers” (paying and non-paying customers)  to  governments,  doctors, nurses,
hospitals and clinics, insurers, employers etc. intermediated by information brokers and
bridging institutions. The ways in which such authority is pooled or divided is determined
by market power and negotiated arrangements which may be understood as designs or
patterns. Such patterns corresponding to or conceived as an information network consist of
"designers", "processors" "senders",  "carriers", "conduits"  and "receivers" which may be
human or machine and involve transfers of digitalised information between them. This
complicates the pinpointing of responsibilities and liability risks. Moreover, information
confers power in immediate interactions, in hierarchies inside networks and in hierarchies
of networks which call for privacy, secrecy, codes, passwords, and firewalls.  Ownable and
lockable databases protected by  firewalls are incompatible with the notion of open
seamless webs. If digitalised information transferred by  "IT" is prized as a commodity, the32
battle over its control to negate its process aspects becomes a cost burden, as observed by
the founder of cybernetics half a century ago in a seminal observation which holds true also
today
34. This complexity points to the need for global governance to reap the maximum
benefits of IT diffusion in healthcare.
There is a good case for competition policy harmonisation at the international level
without which comparisons of role of IT on costs, prices, profits and volumes entail
significant effects of subsidies in developed countries that protect competitivenes. TRIPS
caters to this circumstance through the enabling Article 31 (k), relevant excerpts of which
state:
"Members are not obliged to apply the conditions…..where such use is permitted to
remedy a practice determined after judicial or administrative process to be anti-
competitive"
Federally funded pharmaceutical inventions in U.S.A. subsidise about half of the
American Pharmaceutical industry's research costs with State-aid. When  blind-alleys have
been eliminated by the application of federal funds, gifts of drugs developed in the national
institutes and laboratories are made to enable private capital to develop and commercialise
the final product
35. Pharmaceutical companies'  costs  mainly consist of expenses to acquire
patent rights, obtain FDA approval and preserve exclusive marketing rights. Universities
pledge exclusive rights to the outcome of their government funded research to private firms
in exchange for cash incentives and financing of buildings and laboratories as in the
Wisconsin-Geron, Berkeley-Novartis, Washington-Pharmacia and Colorado-Ribozyme
collaborations. These are about 130 such instances of co-operation in U.S.A. and cross-
border collaborations of this nature are emerging  outside America too in developed and
developing countries
36.
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The reluctance of National Institutes of Health in U.S.A. to dilute intellectual
property rights in commercial licenses to final products developed by firms through parallel
licensing of therapeutic agents and compounds to WHO or some similar other global
institution  is understandable. The Bayh-Dole Act (P.L. 96-517, December 12, 1980)  was
aimed at enhancing American competitiveness, not healthcare and it need not come in the
way of a global compact in the war against disease. Whether new public-private
partnership initiatives of the kind envisaged by Sachs (2001) may circumvent this
technicality, remains more uncertain than the continued existence of statutes (in U.S.A,
Italy, Australia, Philippines, India, China, Malaysia, Singapore, New Zealand, Ireland,
Switzerland and the U.K.) whereby governments may lawfully ignore patents if public
interest requires them to do so. The situation is complicated further by the inviolability of
independent justice systems to interpret national public interest when writs of mandamus
are invoked against governments by individual citizens or in class action suits.   
All kinds of services are marketed as "products". Whether they are regarded
patentable or not could make a difference to market structures, intensity of competition,
cost and price structures for such services and to incentives for pre-emptive patenting. The
need to distinguish the exploitation of patents subsidised by State-aid from those that
reflect  investments in R & D by companies is important. It is not clear whether
compulsory licensing is automatically hindered in the case of the former by the application
of Article 5 of the Paris Convention for the Protection of Industrial Property (once three
years have elapsed from the date of patent) and whether Article 28 of TRIPS would stand
in the way of production for exports (the article only mentions import restrictions) as in
EU's  dispute case against Canada at the WTO (WT/DS/114). In this situation, a patent
looks less like a certificate of ownership and may at best be regarded as a ticket to
litigation. A weak patent backed by a big firm is more effective than a strong patent held by34
a small firm which cannot afford to defend it
37. Almost half of the litigated American
patents (46 % to be precise) were invalidated by courts between 1990 and 1998. Pharma
patents disputes have invariably required IT in the courtrooms too
38.  Thus there is a need
for policy convergence at the global level so that IT and IPR issues may be harmonised in
the interests of trade and healthcare.
VIII The  Evaluation If  It’s Impact
The role of IT in healthcare and its impact through services trade depend on three
inter-related aspects:
(1) power and reach of telematic connectivity which determines who would be
included,
(2) legitimacy of service providers seeking returns on investments, and,
(3) structure of responsibilities for healthcare which are part of the governance frame
in local and national jurisdictions.
Healthcare systems must perform at a "fair" cost to preserve and augment human
capital which is impossible to arrange without cross-border trading in healthcare
commodities and services and some degree of harmonisation of standards. From the
preceding discussion, what consumers, service providers, insurers, governments would
value by the criteria of choice, efficiency and costs is summarised in Table 3 below:
                    
37 The five leading private patenters of human gene uses (Incyte Genomics, Human Genome Sciences, Celera
Genomics, Hyseq and Millenium) are altogether estimated to have made about 27,500 patent applications
and between them obtained  812  U.S. patents upto February 2001. 
38 To quote the Judge in the AZT case," The administrative complexity of conducting a trial of this
magnitude has been enormous for the court and the parties. The sixty year old courtroom in New Bern,
North Carolina has been converted into a high-tech facility using six computer-integrated video display
monitors…"35
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Note:  The design of healthcare products, healthcare systems and healthcare policies is influenced by
motives, preferences and expectations of different stakeholders as  above.36
In Figure 1 above (with its 25 synoptic points of reference), the concerns of the
various interest groups are noted. The rest of this section is concerned with analysing how
IT would  affect all the various interest-groups and their goals and preferences.
Doctors and patients benefit from the way IT enables records to be safely stored,
efficiently retrieved easily updated and quickly transferred. IT promotes awareness. People
easily obtain information concerning diseases, treatments and facilities. Discerning
consumers get to understand their own responsibility as co-producers of their health, and to
evaluate choices. Studies have established that small inputs of TeleHealth resources 
contributed to huge gains in access to healthcare for consumers in Bhutan, Ethiopia, Sri
Lanka, South Africa, Argentina, Mozambique, Taiwan, Saudi Arabia, Thailand and Jordan
39. The participation of individuals in networks as special interest groups where
experiences are shared worldwide strengthen countervailing institutions through which
patient’s rights may be effectively asserted. Service providers respond to incentives to
produce, trade, and link at competitive cost.
Investments in telematic capabilities can strain public finances but these would be
justified where efficiency and equity gains enable returns on such investments through
improved healthcare or reduced costs as attempted in Thailand, South Africa, Brazil,
China, India, Srilanka and Mexico. The question of whether IT adds to costs or reduces costs
could yield different answers depending on how this issue is examined.
40  If we focus on
disease burdens and assess how use of IT affects cost per diagnosis or cost per treated illness,
it would be important to factor in the quality and reliability dimension that IT brings to
healthcare. The weightage to be assigned to quality is not easy to specify because the greater
part of IT’s contribution occurs in healthcare development and healthcare administration, not
in healthcare delivery. Yet healthcare delivery which is directly experienced by patients is
usually the starting point of cost-benefit analysis.
                    
39  Mandil (1998) presents the early international experience of how telehealth propels cross-border trade in
health services.
40 Fuchs and Sox (2001) present a physicians’ perspective of the usefulness of thirty medical innovations
facilitated  by IT and Fox-Rushby, Mills and Walker (2001) propose cost-effectiveness league tables.37
The calculus of costs is altered when IT enabled healthcare databases in genetically
coded information of groups and communities (required by drug developers) are traded as a
quid pro quo to access to healthcare or if tools of IT are used to optimise revenue models for
services providers against consumer needs and interests. Questions of safety, privacy, data
protection and public health that arise in such contexts were discussed in Section 6. Although
these problems are universal in nature, it is necessary to develop safeguards for them
particularly from the perspective of less developed countries where resource scarcity could
render abuses and misuses harder to prevent or remedy. Costs to consumers in the form of
what IT adds to prices of hospital care, outpatient care and prescription drugs or other costs
in the form of loss of privacy and data protection would need to be addressed by policy
measures in all situations where  the demand side is poorly organised and public healthcare
not well resourced.
 
The prospects of widespread use of IT in healthcare delivery in less developed
countries ought to be viewed with caution. Policies would be needed to ensure  that rural
populations are able to afford costs long after short term pilot projects with external
assistance are demonstrated to be feasible.
41 The scope of IT in healthcare would also be
constrained by infrastructure (electricity, telecom bandwidth, maintenance of equipment etc)
and cost in less developed countries and substantial investments would be needed need to
overcome this limitation. TeleHealth services supporting many forms of medical services
including storage, retrieval and transmission of data and images would be very expensive.
Specific targeting of applications which save time, transport costs and have high positive
spillover effects may need to be prioritised.  The labour intensity of health services is to the
                    
41 IT has not been used  for healthcare delivery to  remote locations even in developed countries where
advanced public health systems backed by welfare state guarantees are in place such as Finland, where
such technologies are highly advanced and can be afforded privately as well as publicly. The remote Lapin
Province of Northern Finland spanning the Northern latitudes between 67,25 (Sodankyla) and 69,52
(Utsjoki),has no hospital. Local health centres are understaffed by more than 60% of authorised strength.
The reach of  telemedicine from the nearest hospital in Rovaniemi cannot take care of any serious
emergencies, maternity cases,or surgeries. All diagnostics requiring pathological tests or radiological
scanning and any medical emergencies require  patients to travel to Rovaniemi, involving  road  journeys of
upto 15 hours from Utsjoki.In contrast, Norway, Scotland, and Russia  introduced trade in  telemedicine
successfully.  Tromso (Norway) and Archongelsk (Russia) are  teleconnected with growing two-way trade.. 38
advantage of developing countries which can promote trade while  strengthening national
health systems at the same time.
Diagnosis and treatment practices evolve from a complex mix of regulatory
procedures, disease burden circumstances and the load on service providers. Many less
developed countries lie in  climatic zones that produce a  wide range of infections from
bacteria and viruses. It is difficult to expect convergence in medical practice in some diseases.
It is doubtful that IT could significantly improve the diagnostic context for infectious diseases
 except to the extent of enabling quick second opinions, or transferring results of pathological
tests. However, in applications like heart surgery, cancer treatments, immunisation
procedures, use of diagnostic equipment in surgeries and in the provisioning and distribution
of life-saving medicines, convergence is  promoted by information flows. New epidemics of
non-communicable diseases such as diabetes, cancer and heart disease  spread faster with IT
transmissible life-styles and consumption cultures according to researchers who point to
"fragility of recent health gains" and emphasize the importance of prevention and public
health surveillance in less developed countries where the rising burden of non-communicable
diseases presents a double burden of disease
42.
Healthcare spending is not promotable as a goal in itself and such spending, except in
its preventive or prophylactic aspect, is unrelated to good health, a promotable goal.
Secondly, healthcare spending is context-sensitive to the cost of diagnosis and treatment of
specific illnesses which differ in propensity across countries and also regions within
countries. International comparisons on the basis of spending per capita say nothing about
how much of the health need was met and at what cost per diagnosis or what cost per treated
illness.
43  Fairly detailed cost information on these lines would be needed to know whether IT
has added to costs or reduced costs in relation to the burden of disease. Also, such data would
require to be obtained consistently over a period of time to know how the cost changed. With
                    
42 Brundtland (1999) and Beaglehole and Bonita,(2001) have drawn attention to the dilemma of the double
burden of disease facing developing countries.
43  Navarro (2000) and  Rosen ( 2001) cite these benchmarks to question healthcare  rankings in the World
Health Report 2000.39
reference to Figure 1, IT has raised the costs of drug discovery,  increased efficiency and
reduced costs in drug development and health diagnostics leaving choice largely unaffected,
whereas in healthcare delivery, IT has increased choice and costs but efficiency gains are
marginal and uncertain.
The real gain from connective IT technologies lies in the expansion of choice for
diagnosis and cost-effective treatment of  those communicable diseases and non-
communicable conditions which are hard to diagnose or difficult to treat and for which
gestation periods of treatment innovation may be shortened. The rising incidence of the non-
communicable disease burden can be checked when data on risk factors in less developed
countries is properly recorded with the help of IT and analysed (Beaglehole and Bonita,
2001).
Solutions for regions with a preponderance of communicable disease and low
production and IT capacities would need to differ from regions where non-communicable
diseases are the bigger menace and production capacities can be created to cope with this
aided by a higher quality of IT penetration. The latter category would include Argentina,
Brazil, China, India and Mexico. Problems with so-called "neglected diseases" are not the
responsibility of any particular country nor attributable only to non-availability of medicines.
The introduction of the TRIPS product patent regime may require firms in these countries to
step up research and development activity or sell-out to foreign firms, independent of the
resources of global funds for which they may  compete.
 IT has made marketisation of household production through home workers, call
centres and backroom paperwork  possible in ways previous studies could not anticipate but
this has not improved the situation in most of the least developed countries.
44 There remain
                    
44  Reynolds's "turning point" conjecture when intensive growth overtakes extensive growth (Reynolds, 1983)
applied to a sample of 41 less developed countries, each with population over 10 million persons, shows that
7 countries in this sample could not reach the turning point mainly because of  "remoteness" or "absence of
infrastructure" or both. These seven are Afghanistan, Nepal, Ethiopia, Sudan, Zaire, Mozambique and
Bangladesh. Two decades later the position on remoteness and  infrastructure for these countries is not
much improved.40
more than 80 countries where it should now be possible to introduce trade based on IT’s role
in healthcare but IT presence is barely noticeable. The scale and sophistication of markets
required for IT services to be domestically viable without cross-border trade are rarely present
in least developed countries except for a limited range of business-to business  and enterprise
resource planning  applications.  Firm level data from the chemical, pharmaceutical,
biotechnology, and bioinformatics industries in South Korea, China, Singapore and India
suggests that joint venture subsidiaries with foreign majority control are associated with
greater knowledge transfers and associated spillover effects consistent with the findings in
earlier  Moroccan and Venezuelan studies
45.
This brings pressure  on governments to act on their obligations concerning public
health and healthcare in a manner consistent with policies for trade, investment and
development. The expansion of cross-border parallel trade in intermediate IT services and
products where intellectual property rights are weak and the attempt to stop cross-border
parallel trade in final pharmaceutical products are known to be at the core of this controversy.
The next generation of life saving medicines would come mainly from IT-induced
advances in genomics and proteomics involving genetically modified microorganisms. The
same knowledge can also be used to increase microbial virulence and to bioengineer
microorganisms resistant to drugs and vaccines, which have new ways of spreading, can
escape detection by the body’s defence system, and if desired can also remain latent until
triggered at some later time. While countries may find reasons or loopholes to deny patents
for diagnostic, therapeutic, surgical methods, plants and animals, and biological processes for
the production of plants and animals, the category “microorganisms and microbiological
processes” cannot be denied patents.
In Section 6, it was noted that countries are vulnerable because databases of whole
populations can be maintained privately to target specific populations or ethnic groups
46. This
                    
45 Haddad and Harrison (1993)
46 The human genomes of the populations of Tonga, Estonia and Iceland have been bought and patented by
private companies (http://vector.cshl.org/eugenics.html)41
implies that for the first time in history, ‘ethnic cleansing’  and ‘civil wars’ can be started
without conventional weapons. One of the dangers of the otherwise welcome public-private
partnerships in the offing is the nature of license they provide to firms building databases by
conducting long-distance large scale clinical trials in less developed countries which could
have uses in eugenics or bioterrorism to their detriment  if global health databases remain
under  private ownership or monopoly control 
47.
The Biological Weapons Convention (BWC) prohibits stocking any microorganisms
unless they have therapeutic value. It is very difficult to establish usefulness before clinical
trials are completed. The facilities to stock microorganisms and the rights to hold them are
governed under the Budapest Treaty on Microorganisms and arise in the context of  the
Convention on Biological Diversity, 1992 (Biodiversity Treaty) which recognises the country
of origin of genetic resources. Article 7(d) of the Biodiversity Treaty explicitly provides for
maintaining and organising data with regard to conservation of life forms. Further, its Article
16(3) caters for developing countries to be provided access  to biotechnology protected by
patents. But U.S.A, the only country with access to all microorganisms is not a signatory to
the Biodiversity Treaty, signed and ratified by 157 countries and has refused international
inspections under the Biological Weapons Convention. International consensus is needed for
global databases to be legitimately shared and for countries to adhere to international regimes.
If legitimate access to biological information remains skewed, and without adequate
international safeguards, the biological divide would grow and so would the risk of accidental
or deliberate disease from the actions of terrorists and rogue States.
IT intensity has spread to investigative tools and procedures which can be patented
before biotic matter has been probed. Also, genetic information is patentable as soon as its
elements are identified even before its uses are found or functions decoded. This confers
advance exclusive property rights on potential disease genes
48. The use of IT complicates
                    
47 ‘Bioterrorism’ is malevolent use of bacteria, viruses or toxins against people, animals and plants (NLM,
2000).
48 U.S.A. banned frivolous patenting on January 12, 2001 because every protein molecule target is at least
passable as an  additive for hair shampoo and dog food, or more creatively as low-cholestorol cat food. 42
intellectual property rights in genetic material if DNA sequences of identified elements are
treated as separate inventions,because  any useful product  is  likely to cross boundaries of
several patents
49. An international consensus needs to be evolved so that IPR issues do not
slow down IT-intensive global medical research 
50.
If there is a consensus that TRIPS causes welfare losses of different magnitudes to
different countries due to differences in nationally subsidised IT-intensity in healthcare,
either TRIPS could be renegotiated and modified, or supplemented by a scheme of
international credits and debits to cater to the differential impact on costs and benefits for
developing countries reqquiring differential treatment. This could take an innovative form,
for instance in pooled funds for common causes under international regimes. TRIPS could
also be left as it is but that could force WTO dispute panels of the future to re-write TRIPS
and encourage countries to make their own national interpretations of it until then
51.
Questions about affordable medicines and the incentive for innovation require recognition
of IT’s role in healthcare and agreement on criteria for making the trade-off  between static
equity and dynamic efficiency.
IX Conclusions and Recommendations
What difference does IT make to worldwide production and trade of healthcare
commodities and services  ?  This central question was examined by analysing the
embeddedness of IT in development, delivery and administration of healthcare
commodities and services in cross-border value chains of the international economy with
the following conclusions and recommendations:
1. TeleHealth provides means by which the allocation of healthcare resources can be
improved together with trade promotion. In linking individuals, groups, communities,
                    
49 Bobrow and Thomas, 2001 question the wisdom of granting patents before anyone including the patent-
holder has any clue to the therapeutic significance of  what is sought to be protected.
50 Barton (2001) also cautions against this danger.
51 A compromise introduced for least developed countries to kick-start the Doha Round in November 2001
absolves them of responsibilities under Sections 5 and 7 of Part II of TRIPS until 2016..43
organisations and governments in complex value chains across borders, IT can play an
important role in enabling the world’s poor to access essential health products and
services in innovative forms as discussed in Sections 2 and 3 of this paper. IT has
promoted efficiency by enabling information to be available and cheaply distributed and
improved the prospects for countervailing institutions to function for reasons detailed in
Section 4. These benefits are observable in less developed countries too with IT diffusion.
Information is a pre-requisite of good stewardship and IT enables governments to know
what to regulate and how best making it less likely that commercial interests would claim
precedence over people’s health. More open information flows on deliveries and
deliverables would set norms and standards and new forms of partnership between
private, voluntary and public sectors could be created.
Old institutionalities like Hisba, Ombudsman,  Panchayat could be revitalised as stewards
in local communities or new ones built if even 5 % of total resources allocated to country
specific projects were earmarked for investments in action-research to organise IT’s role
in efficient ways of delivery under local control. This will also help compare
performances, conduct reasoned discourses on  alternatives and provide feedbacks on
much needed public-private partnership experimentation. Decentralised networks and IT
reinforce each other whereas IT costs and risks require syndication and these two contrary
 tendencies pull in opposite directions. Investments in IT for healthcare could be treated as
global public goods and financed internationally.
2. Telematic connectivity conferred by IT is easily diffused technically but structural
impediments inhibit its diffusion in less developed countries. Since the new generation of
healthcare commodities and services are IT-intensive and access to naturally occurring
and mutated microorganisms highly skewed, the digital divide could aggravate the
biopower divide. However, this could be mitigated by aligning financial means and bio-
information needs of firms in developed countries with financial needs and information
rationalised in developing countries through new global institutions and partnerships.44
3. The tension between efficiency and equity is at the core of how IT affects designs of trade
in healthcare services in several important ways:
(a) in design of therapeutic products due to new ways of discovering, synthesising and
testing drugs but incentives require to be structured for IT-intensity to be used for
underfinanced neglected diseases;
(c) in design of networks where transfer pricing of value created at different locations and
e-commerce are a crucial determinant of profitability and growth through cost control
and differential pricing and can reduce response times for development, delivery and
administration of healthcare;
(d) in design of healthcare systems where developing country governments struggle to
build national health systems with strain on public finances while at the same time
investing in telematic capabilities, IT and human capital for cross-border services
trade in healthcare.Attention to the framework presented in Section 8 would call for
policies that ensure that higher healthcare costs induced by IT are commensurate with
benefits by spreading the costs.
4.  Policy conflicts between health, trade and development goals over rights and interests
require international regimes for distributed enterprising, particularly with regard to how
biological resources are shared. The dissolution of traditional industry boundaries between
pharmaceuticals, biotechnology and IT for life sciences has irreversibly transformed the
contestable healthcare arena changing its scope from national to global. Cross-border
trade in health-related IT services has attracted record amounts of FDI for healthcare
development and healthcare administration but not as much for healthcare delivery. The
scale and scope effects for industrial structures point to continuing  consolidation and a
reduction in the number of global players in healthcare businesses.
This poses new challenges to anti-trust legislation and competition policies which would
need to be harmonised globally.
5.  IT enables distance consultation and cross-referrals among professionals where density of45
medical professionals is highly variable across urban and rural areas and the expertise of
specialism difficult to replicate at every location. By promoting low cost distance
interaction among groups for exchange of information, IT expands choices, enables more
productive use of medical resources, and encourages innovations in cross-borde supply of
services as detailed in Sections 2 to 4. Alternative forms of medical treatment such as
kampo, homeopathy, ayurveda, unani, acupuncture, herbal medicine etc. would be more
thoroughly scrutinised and facts separated from conjectures on the basis of information
and experiences shared on websites and in internet discussion groups.
6.  Digitalised connectivity has improved transparency, expanded choice and created new
value chains for all concerned but its impact on costs of healthcare is unclear. This
deserves to be researched further with respect to disease burdens, cost per diagnosis and
cost per treatment for more clarity on policy perspectives. All the  potential  gains from
the role of IT in healthcare in less developed countries are not yet visible in actual gains to
date. This is partly because stewardship requirements in less developed countries are
greater and different from developed countries and because IT is not a substitute for some
of the critical factors contributing to healthcare such as safe drinking water, nutrition,
hygiene and sanitation or poverty. The diffusion of IT to rural areas is also constrained by
non-availability of electricity and the difficulties of maintaining computer equipment in
dust-free and humidity-free settings. The positive impact of IT on healthcare  exports,
growth, and employment has to be weighed against resource diversions, depletions and
strains on public finances. In countries where global networks present limited points of
contact, the positive spillover effects for human capital and infrastructure are negligible.
The reach and power conferred by IT does not translate easily into capacity creation.  Not
much can be concluded about motives and powerbases of those influencing policy
without better clarity through more research and empirical analysis at disaggregated levels
in specific developing countries and in specific kinds of IT applications among clusters of
healthcare service providers and communities. The questions raised in Figure 1 of Section
8 constitute an ongoing research agenda. More research is needed to understand how
market and non-market solutions proposed would actually work. Governments need to46
encourage experimentation on syndication of risks across public systems and private
enterprises through innovations in health insurance and IT investments for healthcare.
7.  The use of IT has spawned and proliferated new fields of knowledge for profit in
healthcare. These have prompted discussions on international collaborations (including
public-private-voluntary inter-sectoral partnerships) for transnational governance of  new
risks for the bundling of product-services linkages as analysed in Section 5.  The
involuntary extraction of  data from humans across borders requires a review of
standards of privacy and data protection laws. Complex questions of personal data
protection, privacy, remote liability and vicarious liability where national  treatments are
yet to be harmonised must remain on the research and policy agenda of the WHO.
Considerable uncertainty remains about prospects for IT-enabled global databases
concerning microorganisms from which the next generation of IT-assisted life-saving
medicines would emerge. This poses health security hazards on an unprecedented scale,
besides rendering TRIPS partially unimplementable. The normative aspects of digitalised
transfers of data are not determined by IT alone and government scrutiny over such
communications are constraints for the notion of seamless connectivity. The responsibility
for healthcare and for IT is naturally global in certain respects. Global governance and
public-private partnerships need to be designed to secure public health, human privacy,
data integrity, intellectual property rights and telematic  trade as discussed in Sections 6 to
8 of this paper. 
8.  Information and communication technologies now enable abusive experimentation to be
undertaken from a distance in the twentyfirst century. The perversion of medical
knowledge and skills towards involuntary, uninformed and coercive participation in trade
of genetic material, expropriation of organs, biological experiments in eugenics, human
safety and ergonomics, is very hard to prevent. In the twentieth century such
experimentation  occurred on minorities in a number of countries on a large scale. The
greatest transformative impact of  IT has arisen in robotics involving the design of expert
systems approximating artificial intelligence with learning capability. IT systems, on the47
basis of learning, could be making decisions not under the control of identifiable humans
or collectivities of human agents and be communicating amongst themselves in languages
not immediately intelligible even to their original programmers
52 .The solutions to
introduce human supervision to mitigate this would further complicate issues of privacy
and data protection
53. There are also implications for the law of extra-territorial liability
and the doctrine of remoteness and international agreement would be needed to   keep
pace with differing national interpretations and avoid the pitfalls listed in Section 6 and
analysed further in Sections 7 and 8.
9.  Independent healthcare standards and regulations bodies are required for the
establishment and interpretation of healthcare trade rules including dispute settlement.
This could be a  joint undertaking of WTO and WHO. Similar to the way fiscal domains
provide for model codes and mutual convergence (for instance in the treatment of non-
residents), international private and professional bodies or inter-governmental bilateral
and multilateral mechanisms are needed to harmonise professional qualifications,
curricula, standards and regulations concerning rights and obligations related to
healthcare. Mutual recognition of healthcare systems and standardisation of data transfers
and telematic platforms are also needed.
IT blurs the boundary between the real and the virtual world. A clarification of the locus
standi principle in private and public law is required to enable foreign national,
supranational or international regulatory authorities concerned in a healthcare matter to
prosecute in national jurisdictions in matters arising from IT based healthcare
development and healthcare delivery. Agreements/Protocols are required whether actions
could be initiated where cause of action has arisen or where the party liable for the action
is located involving some degree of joint regulation among treaty countries on identified
sets of healthcare commitments. The need to create supranational judicial and executive
authorities with powers to require bio-defaulters to be accountable to international control
                    
52  Warwick (1998) and Aggarwal (1998) analyse the perils of unsupervised artificial intellligence applications.
53  Perri 6 (1999, 2001) discusses the problems of human supervision over aertificial intelligence applications.48
as has been done for genocide and war crimes, merits serious consideration. At the same
time national extra-territoriality as in current U.S. trade laws would require to be
circumscribed, supported by agreements on which flows may take place under what
conditions and to what degree of  openness and transparency. The danger that e-business
standards could evolve to reflect the concerns only of developed countries must be
countered through appropriate international regimes in IT consortia as well as WTO for
reasons discussed in Sections 7 and 8.
10. A new international civil service of  transferable regulators under international control of
the WHO or UN as health keepers (like peace keepers) could be created to observe
violations, share information, help develop policies, systems, actions for cooperation at
national and international level and to announce early warning signals before complex
health emergencies arise. The creation of international insurance markets against
regulatory failure also deserves consideration. Health-keeping responsibilities could
initially be limited to liberal democracies  willing to subscribe to international codes of
governance conduct and able to underwrite financial guarantees in favour of independent
international bodies such as globally mandated  healthbanks or healthfunds, with WHO
facilitation. The same healthbanks could act as clearing houses for biobanks, other
healthcare resources and IT-intensive databases held in public-private partnerships.  Since
IT standards are not made at the WTO or WHO, globalising the control of healthcare data
sets could end the conflict between seamless connectivity and firewall solutions.
Healthbanks could also fund the identification and disclosure of genetic information and
microorganisms in the public domain with  proper safeguards.
The imminent expansion of cross-border trade in health related IT and IT-related
healthcare may or may not significantly  alter the calculus of costs and benefits of saving
or prolonging human life and alleviating suffering caused by diseases, accident-inducing
hazards, ageing, improper nutrition, lack of hygiene, disability, humiliation and despair.
The reasons for this uncertainty are traceable to the ways responsibility for healthcare,
authority to design its value chains, and the power and capacity to organise its delivery49
remain separate or come together. The challenging task of creating and resourcing new
international institutions to overcome this uncertainty remains.50
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